SCHEMBL2595321

SCHEMBL2595321

CC(C)n1ncc2c(C(=O)O)cc(Cl)cc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
KMT2A Q03164 2/20 0.49
KMO O15229 2/20 0.42
PDE1A P54750 1/20 0.39
PDE1B Q01064 1/20 0.39
PDE1C Q14123 1/20 0.39
EZH2 Q15910 4/20 0.37
P2RX3 P56373 2/20 0.37
P2RX2 Q9UBL9 2/20 0.37
ACLY P53396 1/20 0.37
AKR1C4 P17516 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
AKR1C1 Q04828 1/20 0.37
EED O75530 1/20 0.36
RBBP4 Q09028 1/20 0.36
SUZ12 Q15022 1/20 0.36
RBBP7 Q16576 1/20 0.36
CYP3A4 P08684 1/20 0.36
NOTUM Q6P988 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2594697 0.85 PDE1A (0.40) KDM4EKMT2AKMOPDE1APDE1B
SCHEMBL23809208 0.84 KDM4E (0.55) KDM4EKMT2APDE1APDE1BPDE1C
SCHEMBL31474839 0.82 KDM4E (0.53) KDM4EKMT2APDE1APDE1BPDE1C
SCHEMBL2588942 0.82 KDM4E (0.53) KDM4EKMT2APDE1APDE1BPDE1C
SCHEMBL12180845 0.82 KDM4E (0.53) KDM4EKMT2APDE1APDE1BPDE1C
SCHEMBL20365096 0.78 ACLY (0.41) KDM4EKMT2AKMOPDE1APDE1B
SCHEMBL12499174 0.78 CREBBP (0.45) KDM4EKMT2AKMOAKR1C4AKR1C3
SCHEMBL2594393 0.76 EZH2 (0.51) KDM4EKMT2AEZH2HPGDHCAR3
SCHEMBL29846416 0.76 EZH2 (0.51) KDM4EKMT2AEZH2HPGDHCAR3
SCHEMBL1694749 0.75 KDM4E (0.71) KDM4EKMT2AKMOPDE1CEZH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP disclosed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-8846935-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2014-09-30 US disclosed
US-8846935-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2014-09-30 US disclosed
US-8846935-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2014-09-30 US disclosed
EP-2566328-A1 INDAZOLES GlaxoSmithKline LLC (US) 2013-03-13 EP disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053383-A1 INDAZOLES IDH3A, CYP3A7, IDH3B KDM4E 2573/4885KMT2A 2540/4885KMO 2770/4885
US-20140350013-A1 INDAZOLES IDH3A, CYP3A7, IDH3B KDM4E 2573/4885KMT2A 2540/4885KMO 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.